Study S001901

An Active-comparator-controlled, Open-label, Parallel Group Study to Evaluate the Effect of Survodutide on Energy Expenditure and Fatty Acid Oxidation in Subjects With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06745284
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 64
Start: 2025-03-26
Primary completion: 2027-01-08
Lead sponsor: Boehringer Ingelheim
Conditions: Obesity
Interventions: DRUG:Survodutide; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:U1111-1309-3679

Registered primary outcomes

Absolute change in sleeping metabolic rate (SMR) (measured in a whole room calorimeter) from baseline to first visit a participant reached at least 10% weight loss [at baseline, up to 36 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.